Abstract YO26
Case summary
As the survival of patients with brain metastases is being prolonged, due to improved systemic therapy, opportunities to use immune checkpoint inhibitor (ICI)s after SRT (stereotactic radiotherapy) or IMRT (Intensity Modulated Radiation Therapy) in patient with brain metastases are increasing. Radiation necrosis is known as a late toxicity of SRT and IMRT. However, few studies have examined the association between ICIs and radiation necrosis. Here we report two cases in which radiation necrosis was exacerbated after ICIs.
Case1: A 30-year-old female diagnosed with nasopharyngeal carcinoma who had direct invasion to the skull base and metastases to the vertebrae. After the concurrent chemoradiation, she had a locoregional recurrence. MRI showed the ring-enhancing lesion around the IMRT-pretreated site of the right temporal lobe, which was considered to be radiation necrosis. One week after the initiation of nivolumab, the patient developed disorientation and a headache. Brain CT showed the exacerbation of radiation necrosis. Corticosteroid administration improved the symptoms. Nivolumab was not reinitiated.
Case2: A 60-year-old male diagnosed with non-small cell lung cancer with brain metastases. He underwent IMRT for the right temporal lobe after undergoing bilateral craniotomy for multiple brain metastases. Because the paralysis progressed, he was performed resection of the brain enhancing lesion. The histopathological examination of the resected brain lesion revealed the presence of diffuse necrosis and gliosis with absence of viable tumor, which was compatible with radiation necrosis. One week after the initiation of atezolizumab, the patient developed hemiparesis. Brain CT showed the exacerbation of radiation necrosis. The patient then started treatment with corticosteroid, and hemiparesis was partly improved. The administration of atezolizumab was discontinued.
Conclusion: We experienced two cases of exacerbation of radiation necrosis following the initiation of the ICIs. Further investigation for the safety of using ICIs in patients with radiation necrosis is warranted.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
174P - Progression of computer aided diagnosis on gastric cancer
Presenter: Yingyan Yu
Session: Poster display session
Resources:
Abstract
175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Presenter: Yu-ting Lee
Session: Poster display session
Resources:
Abstract
176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
Presenter: Jiannan Yao
Session: Poster display session
Resources:
Abstract
177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Presenter: Yosuke Horita
Session: Poster display session
Resources:
Abstract
178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
Presenter: Akihiro Yamamura
Session: Poster display session
Resources:
Abstract
179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
Presenter: Mingyu Chen
Session: Poster display session
Resources:
Abstract
180P - LHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA
Presenter: Dan Wang
Session: Poster display session
Resources:
Abstract
181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Presenter: Andrew Dean
Session: Poster display session
Resources:
Abstract
182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
Presenter: Adarsh Das
Session: Poster display session
Resources:
Abstract
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
Presenter: Pooneh Jabbaripour
Session: Poster display session
Resources:
Abstract